Drugs / Pravibismane
Pravibismane
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02723539 | Mar → Nov 2017 | — | Microbion Corporation | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05174806 | Jun 2022 → Jan 2024 | — | Microbion Corporation | Completed | No outcome recorded |
| Phase 2 | NCT02436876 | May 2016 → Oct 2017 | bacterial infectious disease | Microbion Corporation | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pravibismane | “The initial findings indicate that topical pravibismane was safe and potentially effective treatment for improving recovery from infected chronic ulcers by reducing ulcer size...” PMID 38567778 ↗ Apr 2024 |
| Known as | BisEDT | “MBN-101: a suspension of 150, 375, or 600 microgram (µg)/milliliter (mL) (w:v) BisEDT drug particles in suspension in 3% methylcellulose / 0.5% polysorbate 80 / 10 millimole...” NCT02723539 ↗ |
| Known as | MBN-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02723539 ↗ |
| Modality | Small molecule | — CHEMBL5314962 ↗ |
| Route | Other | “intra-wound local administration of MBN-101” NCT02436876 ↗ |